Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
24 juil. 2024 08h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19 juil. 2024 16h05 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., July 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
17 juil. 2024 16h05 HE
|
Ultragenyx Pharmaceutical Inc.
Alignment with FDA on Phase 3 study primary endpoint of Bayley-4 cognition and key secondary endpoint of Multi-Domain Responder Index (MDRI) Phase 3 study on track to initiate by the end of this...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20 juin 2024 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
13 juin 2024 20h49 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
12 juin 2024 16h05 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
12 juin 2024 16h00 HE
|
Ultragenyx Pharmaceutical Inc.
Agreement reached with FDA that cerebral spinal fluid (CSF) heparan sulfate (HS) can be used as a reasonable surrogate endpoint for accelerated approval Data from existing clinical studies appear...
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
11 juin 2024 17h47 HE
|
Ultragenyx Pharmaceutical Inc.
14-month data show treatment with setrusumab resulted in a large, sustained 67% reduction in annualized fracture rate and persistent median annualized fracture rate of 0.00 (p=0.0014) Treatment...
Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference
04 juin 2024 16h05 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
30 mai 2024 16h00 HE
|
Ultragenyx Pharmaceutical Inc.
Treatment with DTX401 resulted in a statistically significant reduction in daily cornstarch intake at Week 48 (p<0.0001) with maintenance of glucose control Company will host investor call today...